Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress

DUBLIN, May 9, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced presentation of analyses of its previous Phase 3 program evaluating ampreloxetine, an investigational medicine for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) at the International MSA Congress, taking place May 9-11 in Boston, Massachusetts.A subgroup analysis selected as a platform presentation focused on patients with Multiple System Atrophy (MSA ...